Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (6): 600-607.doi: 10.19982/j.issn.1000-6621.20220020
• Original Articles • Previous Articles Next Articles
LI Zhi-wei1, LAI Keng2, LI Tie-gang3, LIANG Zi-chao1, DU Yu-hua2(), ZHANG Jin-xin1(
)
Received:
2022-01-30
Online:
2022-06-10
Published:
2022-06-01
Contact:
DU Yu-hua,ZHANG Jin-xin
E-mail:du.yuhua@163.com;zhjinx@mail.sysu.edu.cn
Supported by:
CLC Number:
LI Zhi-wei, LAI Keng, LI Tie-gang, LIANG Zi-chao, DU Yu-hua, ZHANG Jin-xin. Analysis of adverse treatment outcomes and influencing factors of drug-resistant tuberculosis patients in Guangzhou from 2016 to 2020[J]. Chinese Journal of Antituberculosis, 2022, 44(6): 600-607. doi: 10.19982/j.issn.1000-6621.20220020
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20220020
特征 | 合计(677例) | 未发生组(473例) | 发生组(204例) | 统计检验值 | P值 |
---|---|---|---|---|---|
年龄 | 44(31,57) | 41(29,56) | 50(37,60) | Z=52.470 | <0.001 |
性别 | χ2=3.020 | 0.082 | |||
男性 | 492(72.7) | 334(70.6) | 158(77.5) | ||
女性 | 185(27.3) | 139(29.4) | 46(22.5) | ||
职业分类 | χ2=0.331 | 0.565 | |||
农民 | 71(10.5) | 47(9.9) | 24(11.8) | ||
非农民 | 606(89.5) | 426(90.1) | 180(88.2) | ||
户籍 | χ2=10.350 | 0.001 | |||
广州市内 | 304(44.9) | 232(49.0) | 72(35.3) | ||
广州市外 | 373(55.1) | 241(51.0) | 132(64.7) | ||
是否复治 | χ2=2.819 | 0.093 | |||
是 | 397(58.6) | 267(56.4) | 130(63.7) | ||
否 | 280(41.4) | 206(43.6) | 74(36.3) | ||
是否合并糖尿病 | χ2=22.788 | <0.001 | |||
是 | 117(17.3) | 73(15.4) | 44(21.6) | ||
否 | 539(79.6) | 394(83.3) | 145(71.1) | ||
缺失 | 21(3.1) | 6(1.3) | 15(7.3) | ||
是否吸烟 | χ2=19.793 | <0.001 | |||
是 | 156(23.0) | 109(23.0) | 47(23.0) | ||
否 | 499(73.7) | 358(75.7) | 141(69.1) | ||
缺失 | 22(3.3) | 6(1.3) | 16(7.9) | ||
特征 | 合计(677例) | 未发生组(473例) | 发生组(204例) | 统计检验值 | P值 |
是否饮酒 | χ2=19.596 | <0.001 | |||
是 | 59(8.7) | 42(8.9) | 17(8.4) | ||
否 | 596(88.0) | 425(89.8) | 171(83.8) | ||
缺失 | 22(3.3) | 6(1.3) | 16(7.8) | ||
是否合并病毒性肝炎 | χ2=20.926 | <0.001 | |||
是 | 35(5.1) | 28(5.9) | 7(3.4) | ||
否 | 620(91.6) | 439(92.8) | 181(88.7) | ||
缺失 | 22(3.3) | 6(1.3) | 16(7.9) | ||
是否合并高血压 | χ2=20.531 | <0.001 | |||
是 | 25(3.6) | 20(4.2) | 5(2.5) | ||
否 | 630(93.1) | 447(94.5) | 183(89.7) | ||
缺失 | 22(3.3) | 6(1.3) | 16(7.8) | ||
流动性 | χ2=27.399 | <0.001 | |||
市内流动 | 567(83.8) | 409(86.5) | 158(77.5) | ||
市间流动 | 89(13.1) | 60(12.7) | 29(14.2) | ||
省间流动 | 21(3.1) | 4(0.8) | 17(8.3) | ||
耐药分类 | χ2=8.487 | 0.037 | |||
单耐药/多耐药 | 121(17.9) | 74(15.6) | 47(23.0) | ||
耐多药 | 481(71.0) | 342(72.3) | 139(68.2) | ||
广泛耐药 | 33(4.9) | 22(4.7) | 11(5.4) | ||
缺失 | 42(6.2) | 35(7.4) | 7(3.4) | ||
空洞情况 | χ2=13.169 | 0.004 | |||
无空洞 | 293(43.3) | 219(46.3) | 74(36.3) | ||
有空洞但不在上肺野 | 38(5.6) | 29(6.1) | 9(4.4) | ||
有空洞且在上肺野 | 316(46.7) | 211(44.6) | 105(51.5) | ||
缺失 | 30(4.4) | 14(3.0) | 16(7.8) |
变量 | β值 | s | HR(95%CI)值 | Wald χ2值 | P值 |
---|---|---|---|---|---|
性别 | |||||
女性 | 1 | ||||
男性 | 0.39 | 0.18 | 1.47(1.04~2.09) | 2.155 | 0.031 |
年龄 | 0.02 | 0.00 | 1.02(1.01~1.03) | 3.443 | 0.001 |
职业分类 | |||||
非农民 | 1 | ||||
农民 | 0.08 | 0.24 | 1.08(0.68~1.72) | 0.319 | 0.750 |
户籍 | |||||
广州市内 | 1 | ||||
广州市外 | 0.36 | 0.16 | 1.44(1.05~1.96) | 2.295 | 0.022 |
是否复治 | |||||
否 | 1 | ||||
是 | -0.08 | 0.16 | 0.92(0.67,1.27) | -0.507 | 0.612 |
是否合并糖尿病 | |||||
否 | 1 | ||||
是 | 0.51 | 0.18 | 1.66(1.17~2.36) | 2.846 | 0.004 |
是否吸烟 | |||||
否 | 1 | ||||
是 | 0.15 | 0.18 | 1.16(0.82~1.63) | 0.843 | 0.399 |
是否饮酒 | |||||
否 | 1 | ||||
是 | 0.05 | 0.26 | 1.06(0.63~1.77) | 0.207 | 0.836 |
是否合并病毒性肝炎 | |||||
否 | 1 | ||||
是 | -0.49 | 0.39 | 0.62(0.29~1.31) | -1.257 | 0.209 |
是否合并高血压 | |||||
否 | 1 | ||||
是 | -0.47 | 0.58 | 0.62(0.20~1.95) | -0.809 | 0.418 |
耐药分类 | |||||
单耐药/多耐药 | 1 | ||||
耐多药 | -0.66 | 0.19 | 0.51(0.35~0.75) | -3.412 | 0.001 |
广泛耐药 | -0.50 | 0.35 | 0.61(0.31~1.20) | -1.427 | 0.154 |
流动性 | |||||
市内流动 | 1 | ||||
市间流动 | -0.18 | 0.21 | 0.84(0.55~1.27) | -0.844 | 0.399 |
省间流动 | 0.93 | 0.28 | 2.54(1.46~4.41) | 3.306 | 0.001 |
空洞情况 | |||||
无 | 1 | ||||
有空洞但不在上肺野 | 0.17 | 0.35 | 1.18(0.59~2.37) | 0.475 | 0.635 |
有空洞且在上肺野 | 0.29 | 0.16 | 1.34(0.98~1.83) | 1.839 | 0.066 |
变量 | β值 | s | HR(95%CI)值 | Wald χ2值 | P值 |
---|---|---|---|---|---|
年龄 | 0.01 | 0.01 | 1.01(1.00~1.03) | 2.530 | 0.011 |
性别 | |||||
女性 | 1 | ||||
男性 | 0.18 | 0.19 | 1.20(0.82~1.73) | 0.940 | 0.347 |
户籍 | |||||
广州市内 | 1 | ||||
广州市外 | 0.55 | 0.18 | 1.74(1.21~2.49) | 3.204 | 0.002 |
是否合并糖尿病 | |||||
否 | 1 | ||||
是 | 0.47 | 0.19 | 1.59(1.10~2.32) | 2.441 | 0.015 |
耐药分类 | |||||
单耐药/多耐药 | 1 | ||||
耐多药 | -0.63 | 0.20 | 0.53(0.36~0.79) | -3.104 | 0.002 |
广泛耐药 | -0.36 | 0.36 | 0.70(0.34~1.41) | -1.011 | 0.312 |
流动性 | |||||
市内流动 | 1 | ||||
市间流动 | -0.26 | 0.24 | 0.77(0.49~1.23) | -1.076 | 0.282 |
省间流动 | 0.83 | 0.31 | 2.29(1.26~4.18) | 2.714 | 0.007 |
变量 | β值 | s | HR(95%CI)值 | Wald χ2值 | P值 |
---|---|---|---|---|---|
年龄 | 0.02 | 0.01 | 1.02(1.01~1.03) | 3.464 | 0.001 |
性别 | |||||
女性 | 1 | ||||
男性 | 0.14 | 0.18 | 1.15(0.82~1.63) | 0.812 | 0.417 |
户籍 | |||||
广州市内 | 1 | ||||
广州市外 | 0.57 | 0.17 | 1.77(1.27~2.47) | 3.403 | 0.001 |
是否合并糖尿病 | |||||
否 | 1 | ||||
是 | 0.38 | 0.18 | 1.46(1.02~2.09) | 2.068 | 0.032 |
耐药分类 | |||||
单耐药/多耐药 | 1 | ||||
耐多药 | -0.68 | 0.18 | 0.50(0.36~0.72) | -3.842 | <0.001 |
广泛耐药 | -0.46 | 0.35 | 0.63(0.32~1.24) | -1.006 | 0.315 |
流动性 | |||||
市内流动 | 1 | ||||
市间流动 | -0.23 | 0.23 | 0.80(0.51~1.24) | -1.006 | 0.315 |
省间流动 | 0.82 | 0.28 | 2.27(1.32~3.92) | 2.955 | 0.003 |
[1] | World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[2] |
Cannon LL, Oladimeji KE, Goon DT. Socio-economic drivers of drug-resistant tuberculosis in Africa: a scoping review. BMC Public Health, 2021, 21(1): 488. doi: 10.1186/s12889-021-10267-0.
doi: 10.1186/s12889-021-10267-0 URL |
[3] |
申丽君, 王艺曈, 李雪, 等. 基于疗程费用测算耐药结核病患者药物负担. 中国防痨杂志, 2019, 41(9): 962-967. doi: 10.3969/j.issn.1000-6621.2019.09.010.
doi: 10.3969/j.issn.1000-6621.2019.09.010 |
[4] |
Walker IF, Shi O, Hicks JP, et al. Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients. Eur Respir J, 2019, 54(1):1800353. doi: 10.1183/13993003.00353-2018.
doi: 10.1183/13993003.00353-2018 |
[5] |
Christoper KL, Melissa S. Treatment outcomes and factors associated with unfavourable outcome among previously treated tuberculosis patients with isoniazid resistance in four regions of Cameroon. Pan Afr Med J, 2020, 37: 45. doi: 10.11604/pamj.2020.37.45.25684.
doi: 10.11604/pamj.2020.37.45.25684 |
[6] |
Mataambo R, Takarinda KC, Thekkur P, et al. Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015. PLoS One, 2020, 15(4): e0230848. doi: 10.1371/journal.pone.0230848.
doi: 10.1371/journal.pone.0230848 URL |
[7] |
Safaev K, Parpieva N, Liverko I, et al. Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013-2018. Int J Environ Res Public Health, 2021, 18(9):4663. doi: 10.3390/ijerph18094663.
doi: 10.3390/ijerph18094663 |
[8] |
Arroyo LH, Ramos ACV, Yamamura M, et al. Predictive model of unfavorable outcomes for multidrug-resistant tuberculosis. Rev Saude Publica, 2019, 53:77. doi: 10.11606/s1518-8787.2019053001151.
doi: 10.11606/s1518-8787.2019053001151 URL |
[9] | 中华人民共和国国家卫生和计划生育委员会. WS 288-2017肺结核诊断. 2017-11-09. |
[10] | 中华人民共和国国家卫生健康委员会. 中国结核病预防控制工作技术规范(2020年版). 2020-04-02. |
[11] |
刘俊萍, 孙彦波, 张淑兰, 等. 中国耐多药结核不良治疗结局情况的Meta分析. 中国循证医学杂志, 2021, 21(10): 1174-1178. doi: 10.7507/1672-2531.202106123.
doi: 10.7507/1672-2531.202106123 |
[12] |
Ahuja SD, Ashkin D, Avendanon M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med, 2012, 9(8): e1001300. doi: 10.1371/journal.pmed.1001300.
doi: 10.1371/journal.pmed.1001300 URL |
[13] |
Mohd SN, Shah SA, Kamaludin F. Predictors of death among drug-resistant tuberculosis patients in Kuala Lumpur, Malaysia: A retrospective cohort study from 2009 to 2013. J Glob Antimicrob Resist, 2016, 6:102-107. doi: 10.1016/j.jgar.2016.04.005.
doi: 10.1016/j.jgar.2016.04.005 URL |
[14] |
Makhmudova M, Maxsumova Z, Rajabzoda A, et al. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan. Int J Tuberc Lung Dis, 2019, 23(3): 331-336. doi: 10.5588/ijtld.18.0311.
doi: 10.5588/ijtld.18.0311 pmid: 30871664 |
[15] |
Azeez A, Ndege J, Mutambayi R. Associated factors with unsuccessful tuberculosis treatment outcomes among tuberculosis/HIV coinfected patients with drug-resistant tuberculosis. Int J Mycobacteriol, 2018, 7(4): 347-354. doi: 10.4103/ijmy.ijmy_140_18.
doi: 10.4103/ijmy.ijmy_140_18 URL |
[16] |
Getie A, Alemnew B. Tuberculosis Treatment Outcomes and Associated Factors Among Patients Treated at Woldia General Hospital in Northeast Ethiopia: An Institution-Based Cross-Sectional Study. Infect Drug Resist, 2020, 13: 3423-3429. doi: 10.2147/idr.S275568.
doi: 10.2147/idr.S275568 URL |
[17] |
Perez-Navarro LM, Restrepo BI, Fuentes-Dominguez FJ, et al. The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes. Tuberculosis (Edinb), 2017, 103:83-91. doi: 10.1016/j.tube.2017.01.006.
doi: 10.1016/j.tube.2017.01.006 URL |
[18] |
Gautam S, Shrestha N, Mahato S, et al. Diabetes among tuberculosis patients and its impact on tuberculosis treatment in South Asia: a systematic review and meta-analysis. Sci Rep, 2021, 11(1):2113. doi: 10.1038/s41598-021-81057-2.
doi: 10.1038/s41598-021-81057-2 |
[19] |
张海清, 李莉, 吴云亮, 等. 2016-2020年徐州市肺结核合并糖尿病患者流行病学特征及转归分析. 江苏预防医学, 2021, 32(5): 597-598. doi: 10.13668/j.issn.1006-9070.2021.05.030.
doi: 10.13668/j.issn.1006-9070.2021.05.030 |
[20] |
Ruslami R, Nijland HM, Adhiarta IG, et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother, 2010, 54(3): 1068-1074. doi: 10.1128/AAC.00447-09.
doi: 10.1128/AAC.00447-09 pmid: 20038625 |
[21] |
杨列昕, 赵曰科, 邵晶, 等. 基于Cox模型的初治肺结核患者中断治疗研究. 职业与健康, 2015, 31(24): 3458-3463. doi: 10.13329/j.cnki.zyyjk.2015.1183.
doi: 10.13329/j.cnki.zyyjk.2015.1183 |
[22] | 广州市卫生和计划生育委员会. 广州市卫生计生委关于印发广州市“十三五”结核病防治规划的通知. 2017-12-26. |
[23] |
Zingoni ZM, Chirwa T, Todd J, et al. Competing risk of mortality on loss to follow-up outcome among patients with HIV on ART: a retrospective cohort study from the Zimbabwe national ART programme. BMJ Open, 2020, 10(10): e036136. doi: 10.1136/bmjopen-2019-036136.
doi: 10.1136/bmjopen-2019-036136 URL |
[24] | 广州市统计局. 2020年广州市人口规模及分布情况[统计公报][EB/OL].(2021-05-28)[2022-03-15]. 广州:广州市统计局, 2021. http://tjj.gz.gov.cn/tjgb/qtgb/content/post_7306014.html. |
[25] | William G, Alarcon E, Jittimanee S, et al. Care during the continuation phase. Int J Tuberc Lung Dis, 2008, 12(7): 731-735. |
[26] |
Bam TS, Gunneberg C, Chamroonsawasdi K, et al. Factors affecting patient adherence to DOTS in urban Kathmandu, Nepal. Int J Tuberc Lung Dis, 2006, 10(3): 270-276.
pmid: 16562706 |
[27] | O'boyle SJ, Power JJ, Ibrahim MY, et al. Factors affecting patient compliance with anti-tuberculosis chemotherapy using the directly observed treatment, short-course strategy(DOTS). Int J Tuberc Lung Dis, 2002, 6(4): 307-312. |
[28] |
Molie T, Teklemariam Z, Klinkenberg E, et al. Intensive phase treatment outcome and associated factors among patients treated for multi drug resistant tuberculosis in Ethiopia: a retros-pective cohort study. BMC Infect Dis, 2019, 19(1): 818. doi: 10.1186/s12879-019-4411-7.
doi: 10.1186/s12879-019-4411-7 URL |
[29] |
Singh A, Prasad R, Balasubramanian V, et al. Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives. HIV AIDS (Auckl), 2020, 12:9-31. doi: 10.2147/HIV.S193059.
doi: 10.2147/HIV.S193059 |
[30] |
Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J, 2009, 33(5): 1085-1094. doi: 10.1183/09031936.00155708.
doi: 10.1183/09031936.00155708 pmid: 19164345 |
[31] |
Bisson GP, Bastos M, Campbell JR, et al. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet, 2020, 396(10248): 402-411. doi: 10.1016/S0140-6736(20)31316-7.
doi: 10.1016/S0140-6736(20)31316-7 URL |
[1] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[2] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[3] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[4] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[5] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[6] | Yang Haixia, Zhang Xiaoyan, Huang Yi, Li Qiu. Effective and safety of concurrent intensity-modulated radiotherapy and anti-tuberculosis chemotherapy in patients with active pulmonary tuberculosis comorbid with thoracic tumor [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 312-321. |
[7] | Liu Juxiu, Zhang Jianhua, Wen Junjun, Jiang Xiaoshuang. Analysis and trend prediction of Mycobacterium tuberculosis drug resistance in Jilin City [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 348-354. |
[8] | Xue Yu, Yang Xinting, Wang Guirong, Liu Fangchao, Lei Xuan, Zhang Jing, Li Liang. Analysis of risk factors for death in emergency pulmonary tuberculosis patients and risk model construction [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 189-194. |
[9] | Wang Dafu, Ma Xiaoxue, Wang Yun, Li Fudong, Rao Wen, Gong Tingting, Li Shijun, Li Jinlan. Analysis of risk factors for patient delay and adverse treatment outcomes among patients with pulmonary tuberculosis and diabetes mellitus in Guizhou Province, 2016—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 201-209. |
[10] | Liang Linlong, Pei Yi, Zhou Haiyi, Xie Qifang, Zhang Feng, Jiang Jie, Liu Fuqiang. The epidemiological characteristics and trends of tuberculosis among children aged 0-14 years in Hunan Province from 2014 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 29-35. |
[11] | Li Fudong, Ma Xiaoxue, Zhou Jian, Wang Dafu, Zhang Yueying, Gong Tingting, Rao Wen, Hong Feng, Li Shijun, Li Jinlan. Characteristics and treatment outcome analysis of MTB/HIV dual infection patients in Guizhou Province from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 36-43. |
[12] | Chen Jifei, Huang Lihua, Luo Lanbo, Sui Wenxian, Pang Yu, Liu Aimei. Evaluation the efficacy of tongue swab-based PCR fluorescence probe method for pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 51-60. |
[13] | Shi Yilin, Gu Yan. Meta-analysis of the efficacy, adverse reactions, and fatality rate of glucocorticoid combined with anti-tuberculosis drugs in the treatment of tuberculous serositis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 77-86. |
[14] | Fan Jun, Wang Heng, Lan Tinglong, Dong Weijie, Tang Kai, Li Yuan, Yan Guangxuan, Xu Shangsheng, Kang Zhigang, Qin Shibing. Clinical characteristics and surgical outcomes of 12 cases of non-tuberculous mycobacterial spondylitis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 87-95. |
[15] | Ye Zhiteng, Ren Fei, Wang Hua, Yang Ming, Chen Yu, Chen Xiaohong, Wang Yun, Fan Lin. Treatment outcomes and influencing factors in elderly patients with multidrug/rifampicin-resistant pulmonary tuberculosis: a national multicenter, retrospective cohort study [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1023-1029. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||